Medical device industry: growth holds, reimbursement bites

What’s changing in medical devices industry earnings this quarter

The strongest organic growers this quarter led with new products and digital tools rather than volume alone. Straumann’s gains in EMEA and North America came from premium implantology, with China recovering sequentially, while its expanding digital ecosystem, including new scanner and platform launches, is broadening the base for further adoption. Ambu’s completed SureSight portfolio and expanding AI partnerships in bronchoscopy reinforced its lead in single-use conversion, and Ottobock’s prosthetics and neuro-orthotics launches underpinned its strongest regional performance.

Divergence from that broadly positive picture was almost always policy or reimbursement driven rather than demand driven. Organogenesis faced a severe reset in Advanced Wound Care tied to reimbursement changes, and ConvaTec saw a similar decline in its InnovaMatrix line, distinct from the broader growth across its Wound Care business. Coloplast’s Biologics segment faced a comparable decline tied to Medicare reimbursement changes, alongside a related impairment charge.

Cost pressure from tariffs, currency, and inflation featured across nearly every company, with outcomes depending on how much of it could be offset. Coloplast and Teleflex both cited foreign exchange and tariff costs as a direct drag on margins, while Enovis and Embla Medical pointed to tariff refunds that partly cushioned the impact, and Getinge’s margin recovery leaned heavily on a one-off tariff refund alongside underlying productivity gains. Against that backdrop, portfolio reshaping accelerated: Teleflex completed a large OEM divestiture to fund debt reduction and buybacks, Enovis divested its Dr. Comfort business, Ottobock acquired Blatchford Norway, and Getinge acquired Pennamed to expand its infection prevention offering.

Three companies worth a closer look

Straumann: Net sales grew 5.9% to €755 million, with premium implantology and digital solutions leading gains across LATAM, EMEA, and North America. Currency effects pulled the reported EBIT margin down slightly, but at constant exchange rates it improved on manufacturing productivity and supply-chain optimization, and the company raised its full-year outlook.

Teleflex: Net sales rose 28.9% to €506 million on strong Vascular and Surgical performance, though margin declined 7.8 points as integration costs from the Vascular Intervention acquisition weighed on profitability. The company completed a large OEM divestiture, redirecting proceeds toward debt reduction and buybacks, and advanced new product launches including FDA approval for its freeze-dried plasma product.

Organogenesis: Net product revenue fell 56.8% to €39 million as Advanced Wound Care sales dropped sharply following reimbursement changes, with losses widening as gross margin compressed. Management continued investing in its ReNu program, framing the near-term pressure as a step in a longer-term regenerative medicine strategy.

Competitor intelligence at earnings speed

This summary covers Q2 2026 across a selection of companies in the medical device industry. Each summary brings together what a full earnings season would otherwise take days to piece together:

• A synthesis of the cross-company themes shaping the quarter
• Sentiment scoring across five dimensions: revenue development, profit development, market conditions, revenue outlook, and profit outlook
• Company-by-company breakdowns of results and drivers
• Forward-looking signals and guidance from management

The Valona platform extends the same structured analysis to each company individually, updated as new earnings and disclosures are published.

Earnings analysis is only useful when it’s consistent, evidence-based, and comparable across companies and quarters. Applying the same framework every time turns a quarter’s worth of transcripts and disclosures into a dependable input for competitive intelligence, rather than commentary that depends on memory or individual interpretation Learn more about earnings analysis.